US03767D1081 - Common Stock

**APEN** gets a fundamental rating of **1** out of 10. The analysis compared the fundamentals against 187 industry peers in the **Health Care Equipment & Supplies** industry. Both the profitability and financial health of **APEN** have multiple concerns. **APEN** is valied quite expensively at the moment, while it does show a decent growth rate.

In the past year **APEN** has reported a negative cash flow from operations.

In the past 5 years **APEN** always reported negative operating cash flow.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | N/A | ||

ROE | N/A | ||

ROIC | N/A |

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

With a **Gross Margin** value of **55.20%**, **APEN** perfoms like the industry average, outperforming **52.58%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **APEN** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 55.2% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.92%

GM growth 5Y-2.23%

The number of shares outstanding for **APEN** has been increased compared to 1 year ago.

Looking at the **Altman-Z score**, with a value of **-0.16**, **APEN** is doing worse than **60.56%** of the companies in the same industry.

A Debt/Equity ratio of **1.04** is on the high side and indicates that **APEN** has dependencies on debt financing.

Looking at the **Debt to Equity ratio**, with a value of **1.04**, **APEN** is doing worse than **79.34%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.04 | ||

Debt/FCF | N/A | ||

Altman-Z | -0.16 |

ROIC/WACCN/A

WACC10.2%

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.35 | ||

Quick Ratio | 1.89 |

The **Revenue** has been growing slightly by **3.63%** on average over the past years.

EPS 1Y (TTM)-9.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.21%

Revenue 1Y (TTM)22.01%

Revenue growth 3Y14.87%

Revenue growth 5Y3.63%

Sales Q2Q%31.8%

Based on estimates for the next years, **APEN** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **11.79%** on average per year.

EPS Next Y13.1%

EPS Next 2Y11.79%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year18.29%

Revenue Next 2Y20.22%

Revenue Next 3Y33.84%

Revenue Next 5YN/A

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The **Price/Earnings Ratio** is negative for **APEN**. In the last year negative earnings were reported.

Also next year **APEN** is expected to report negative earnings again, which makes the also the **Forward Price/Earnings** Ratio negative.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.79%

EPS Next 3YN/A

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**APOLLO ENDOSURGERY INC**

NASDAQ:APEN (4/3/2023, 7:15:00 PM)

After market: 9.99 -0.01 (-0.1%)**10**

**+0.08 (+0.81%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap475.49M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | N/A | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 55.2% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.7

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.04 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.35 | ||

Quick Ratio | 1.89 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-9.99%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y13.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)22.01%

Revenue growth 3Y14.87%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y